{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chen YP"],"funding":["Hong Kong Baptist University","Southern Medical University"],"pagination":["753425"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9136080"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10"],"pubmed_abstract":["Stroke is a cerebrovascular event with cerebral blood flow interruption which is caused by occlusion or bursting of cerebral vessels. At present, the main methods in treating stroke are surgical treatment, statins, and recombinant tissue-type plasminogen activator (rt-PA). Relatively, traditional Chinese medicine (TCM) has widely been used at clinical level in China and some countries in Asia. Xiao-Xu-Ming decoction (XXMD) is a classical and widely used prescription in treating stroke in China. However, the material basis of effect and the action principle of XXMD are still not clear. To solve this issue, we designed a new system pharmacology strategy that combined targets of XXMD and the pathogenetic genes of stroke to construct a functional response space (FRS). The effective proteins fr"],"journal":["Frontiers in cell and developmental biology"],"pubmed_title":["Detecting Key Functional Components Group and Speculating the Potential Mechanism of Xiao-Xu-Ming Decoction in Treating Stroke."],"pmcid":["PMC9136080"],"funding_grant_id":["SDF13-1209-P01 SDF15-0324-P02(b) SDF19-0402-P02 RC/IRCs/17-18/04","G820282016"],"pubmed_authors":["Wu J","Guan DG","Wu Q","Cai JQ","Wang KX","Li R","Meng W","Chen YP","Li Y","Yu HL","Wang HD","Huang MB","Yin CH"],"additional_accession":[]},"is_claimable":false,"name":"Detecting Key Functional Components Group and Speculating the Potential Mechanism of Xiao-Xu-Ming Decoction in Treating Stroke.","description":"Stroke is a cerebrovascular event with cerebral blood flow interruption which is caused by occlusion or bursting of cerebral vessels. At present, the main methods in treating stroke are surgical treatment, statins, and recombinant tissue-type plasminogen activator (rt-PA). Relatively, traditional Chinese medicine (TCM) has widely been used at clinical level in China and some countries in Asia. Xiao-Xu-Ming decoction (XXMD) is a classical and widely used prescription in treating stroke in China. However, the material basis of effect and the action principle of XXMD are still not clear. To solve this issue, we designed a new system pharmacology strategy that combined targets of XXMD and the pathogenetic genes of stroke to construct a functional response space (FRS). The effective proteins fr","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-05-06T03:20:09.09Z","creation":"2025-05-18T12:06:24.187Z"},"accession":"S-EPMC9136080","cross_references":{"pubmed":["35646921"],"doi":["10.3389/fcell.2022.753425"]}}